CN102665759B - 人源化抗il-22ra抗体 - Google Patents

人源化抗il-22ra抗体 Download PDF

Info

Publication number
CN102665759B
CN102665759B CN201080052724.0A CN201080052724A CN102665759B CN 102665759 B CN102665759 B CN 102665759B CN 201080052724 A CN201080052724 A CN 201080052724A CN 102665759 B CN102665759 B CN 102665759B
Authority
CN
China
Prior art keywords
antibody
human
humanized antibody
humanized
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080052724.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102665759A (zh
Inventor
R·贝克曼
C·约翰逊-莱杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Merck Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41565648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102665759(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono SA filed Critical Merck Serono SA
Publication of CN102665759A publication Critical patent/CN102665759A/zh
Application granted granted Critical
Publication of CN102665759B publication Critical patent/CN102665759B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201080052724.0A 2009-11-19 2010-11-12 人源化抗il-22ra抗体 Expired - Fee Related CN102665759B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09176525 2009-11-19
EP09176525.5 2009-11-19
US26299809P 2009-11-20 2009-11-20
US61/262,998 2009-11-20
PCT/EP2010/067332 WO2011061119A1 (en) 2009-11-19 2010-11-12 Humanized antibodies against human il-22ra

Publications (2)

Publication Number Publication Date
CN102665759A CN102665759A (zh) 2012-09-12
CN102665759B true CN102665759B (zh) 2015-09-30

Family

ID=41565648

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080052724.0A Expired - Fee Related CN102665759B (zh) 2009-11-19 2010-11-12 人源化抗il-22ra抗体

Country Status (20)

Country Link
US (1) US8545844B2 (enExample)
EP (1) EP2512511B1 (enExample)
JP (1) JP5818804B2 (enExample)
KR (1) KR20120098783A (enExample)
CN (1) CN102665759B (enExample)
AU (1) AU2010321047B2 (enExample)
BR (1) BR112012012003A2 (enExample)
CA (1) CA2778864C (enExample)
EA (1) EA021356B1 (enExample)
EC (1) ECSP12011980A (enExample)
ES (1) ES2531996T3 (enExample)
IL (1) IL219740A0 (enExample)
IN (1) IN2012DN03362A (enExample)
MX (1) MX2012005791A (enExample)
NZ (1) NZ599438A (enExample)
PE (1) PE20121560A1 (enExample)
PH (1) PH12012500924A1 (enExample)
UA (1) UA105405C2 (enExample)
WO (1) WO2011061119A1 (enExample)
ZA (1) ZA201202793B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007004770A (es) * 2004-10-22 2007-11-22 Zymogenetics Inc Anticuerpos anti-il-22ra y moleculas y metodos para usarlos en inflamacion.
HUE039849T2 (hu) 2011-03-16 2019-02-28 Argenx Bvba CD70 elleni ellenanyagok
CN107318267B (zh) 2013-08-12 2021-08-17 豪夫迈·罗氏有限公司 用于治疗补体相关的病症的组合物和方法
PE20161440A1 (es) * 2014-05-01 2017-01-26 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
JP2018536650A (ja) 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
ES2966133T3 (es) * 2016-03-18 2024-04-18 Staidson Beijing Biopharmaceuticals Co Ltd Proteína de fusión que comprende el factor de crecimiento nervioso y método de preparación y uso de la misma
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
EP3630182A4 (en) * 2017-05-24 2021-02-24 Development Center for Biotechnology HUMANIZED ANTIBODIES TO GLOBO H AND THEIR USE IN CANCER TREATMENT
KR102611853B1 (ko) 2017-06-30 2023-12-08 자임워크스 비씨 인코포레이티드 안정화된 키메라 fabs
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
WO2023232789A1 (en) * 2022-06-03 2023-12-07 Leo Pharma A/S Liquid formulation of il-22r antibody
WO2024184333A1 (en) 2023-03-08 2024-09-12 Leo Pharma A/S Il-22r antibody for use in treating atopic dermatitis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
MX2007004770A (es) * 2004-10-22 2007-11-22 Zymogenetics Inc Anticuerpos anti-il-22ra y moleculas y metodos para usarlos en inflamacion.
KR20070114324A (ko) * 2005-03-25 2007-11-30 글리카트 바이오테크놀로지 아게 Ｍｃｓｐ 에 향하며 증가된 ｆｃ 수용체 결합 친화도 및효과기 작용을 갖는 항원 결합 분자
CA2631961A1 (en) * 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling relating to antibodies that bind to il-22

Also Published As

Publication number Publication date
BR112012012003A2 (pt) 2016-11-29
ES2531996T3 (es) 2015-03-23
EP2512511B1 (en) 2015-01-07
EA021356B1 (ru) 2015-05-29
CA2778864A1 (en) 2011-05-26
ECSP12011980A (es) 2012-07-31
MX2012005791A (es) 2012-07-03
ZA201202793B (en) 2013-06-26
IN2012DN03362A (enExample) 2015-10-23
CA2778864C (en) 2017-06-27
AU2010321047A1 (en) 2012-05-24
WO2011061119A1 (en) 2011-05-26
PE20121560A1 (es) 2012-12-05
AU2010321047B2 (en) 2016-06-09
NZ599438A (en) 2013-12-20
PH12012500924A1 (en) 2012-11-26
EA201290360A1 (ru) 2012-11-30
CN102665759A (zh) 2012-09-12
JP2013511267A (ja) 2013-04-04
US20120230990A1 (en) 2012-09-13
KR20120098783A (ko) 2012-09-05
UA105405C2 (ru) 2014-05-12
US8545844B2 (en) 2013-10-01
IL219740A0 (en) 2012-07-31
JP5818804B2 (ja) 2015-11-18
EP2512511A1 (en) 2012-10-24

Similar Documents

Publication Publication Date Title
CN102665759B (zh) 人源化抗il-22ra抗体
US20210301028A1 (en) Composition and methods for anti-tnfr2 antibodies
US20200277366A1 (en) MULTI-SPECIFIC ANTIBODY MOLECULES HAVING SPECIFICITY FOR TNF-ALPHA, IL-17A and IL-17F
CN107921122A (zh) 与cd38结合的抗体治疗剂
CN103635490A (zh) 用作治疗剂的可溶性蛋白
CN111971090A (zh) 双特异性egfr/cd16抗原结合蛋白
EP4292611A1 (en) Anti-cd112r antibody and use thereof
CN119768425A (zh) 抗-tl1a抗体及其使用方法
CA2906539A1 (en) Anti-cd52 antibodies
US20220112258A1 (en) Bifunctional molecules with il-7 activity
EP3233120A1 (en) Il-21 antibodies
WO2023061005A1 (zh) 新型抗体-细胞因子融合蛋白及其制备方法和用途
WO2022247826A1 (zh) 靶向pd-l1和cd73的特异性结合蛋白
CN119798438B (zh) 一种抗ccr8单克隆抗体及其应用
HK1171664A (en) Humanized antibodies against human il-22ra
WO2024046301A1 (zh) 包含taci多肽的融合蛋白及其用途
HK40118644A (zh) 抗-tl1a抗体及其使用方法
TW202334218A (zh) 新型抗ｌａｇ３抗體
CN121159699A (zh) 抗Trop2/CD3的双特异性抗体及其应用
CN120344264A (zh) 突变体il-2多肽和il-2前药
HK40106257A (zh) 新型抗sirpa抗体
CN110300763A (zh) 用于治疗白癜风的抗人cxcr3抗体
OA17634A (en) Anti-CD52 antibodies.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1171664

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150930

Termination date: 20191112

CF01 Termination of patent right due to non-payment of annual fee